Family Med Journals

Family Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reich K et al. – Patients with moderate–to–severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided significant QoL improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated.

Related Articles

Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09    Relevance Score: 95%

FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09    Relevance Score: 91%

Study shows major burden of psoriasis
Internet Source, 10/29/09    Relevance Score: 91%

Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09    Relevance Score: 91%

Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09    Relevance Score: 91%

Today in Clinical Pharmacology...keeping you current

Psychoactive Medications and Falls
Geriatrics & Aging, 12/01/09

Efficacy, safety, and tolerability of microsphere adapalene vs. conventional adapalene for acne vulgaris
International Journal of Dermatology, 12/01/09

Continuation of Low-Dose Aspirin in Peptic Ulcer Bleeding. A Randomized Trial
Annals of Internal Medicine, 12/01/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address